TCT-152 Is There a Therapeutic Window For Platelet Responsiveness Among PCI Patients? Analysis from the ADAPT-DES Study  by Kirtane, Ajay J. et al.
Eptiﬁbatide
(n = 561)
Abciximab
(n = 1522) p value
Age 63.8814.1 62.1016.1 0.098
Gender (female) 139 (24.8%) 349(22.9%) 0.382
Previous MI 89(15.9%) 189(12.8%) 0.071
Previous CABG 23(4.1%) 40(2.7%) 0.114
Previous PCI 72 (12.8%) 139 (9.4%) 0.028
Hypercholesterolaemia 298 (53.1%) 462 (42.4%) <0.001
Hypertension 261(46.5%) 615(45.0%) 0.546
DM 93(18.0%) 268(17.8%) 0.947
eGFR<60 112(19.9%) 315 (20.7%) 0.851
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Background: Premature discontinuation of clopidogrel after drug-eluting stent (DES)
implantation increases the risk of adverse cardiac events. Factors associated with
premature discontinuation, however, are poorly understood.
Methods: Patients who discontinued clopidogrel before 1 year after percutaneous
coronary intervention (PCI) with DES were compared to patients who continued
clopidogrel for at least 1 year in this retrospective cohort study. Patients with
cardiogenic shock were excluded. Reasons for discontinuation of clopidogrel were
also collected. Insurance was categorized as private, Medicare, Medicaid, and unin-
sured. Multivariable logistic regression, stratiﬁed by age 65 years, was performed to
identify socioeconomic and clinical factors independently associated with premature
(<1 year) clopidogrel discontinuation.
Results: Among 4841 patients that received DES, 21.9% discontinued clopidogrel
before 1 year. The most common reasons for clopidogrel discontinuation were
physician decision (56.9%) and bleeding (16.9%). Overall, 53.8% of patients had
private insurance, 42.1% Medicare, 2.9% Medicaid, and 1.2% were uninsured.
Median household income by population was not associated with premature discon-
tinuation in the overall cohort. Among the population <65 years, patients with
Medicare, lack of insurance, major bleeding, and history of PCI or congestive heart
failure were more likely to discontinue clopidogrel prematurely. For the population
65 years, patients on warfarin therapy or with history of PCI were more likely, and
patients with history of hypertension or CABG were less likely, to discontinue clo-
pidogrel prematurely (Table).Age <65 Age 65
Odds ratio 95% CI p value Odds ratio 95% CI p value
Medicare 1.64 1.06-2.53 0.03 1.04 0.77-1.42 0.78
Medicaid 1.04 0.55-1.97 0.89 1.02 0.24-4.27 0.98
Uninsured 3.37 1.66-6.85 <0.001 N/A N/A N/A
African-
American
1.24 0.91-1.69 0.17 1.2 0.91-1.60 0.2
Warfarin 0.95 0.49-1.87 0.89 1.86 1.26-2.75 0.002
Major
bleeding
3.68 1.11-12.1 0.03 2.8 0.73-10.7 0.13
Hematocrit
(per 5%)
1.01 0.95-1.08 0.71 0.88 0.77-1.00 0.05
Male 1.23 0.91-1.67 0.18 1.01 0.77-1.32 0.95
Acute
Coronary
Syndrome
1.12 0.76-1.64 0.58 1.29 0.89-1.89 0.18
Previous PCI 1.75 1.33-2.31 <0.001 1.38 1.07-1.78 0.01
Previous
CABG
0.9 0.62-1.30 0.56 0.73 0.54-0.98 0.04
Hypertension 0.86 0.59-1.24 0.41 0.64 0.44-0.92 0.02
Congestive
heart failure
1.76 1.16-2.68 0.008 1.36 0.96-1.91 0.08
MV disease 315(56.6%) 809(57.3%) 0.686
Card Shock 29(5.2%) 94(6.3%) 0.404
Access (radial) 339 (60.5%) 722(48.3%) <0.001
Procedural Success 524 (93.4%) 1407(92.4%) 0.139Conclusions: Premature discontinuation of clopidogrel is common among patients
undergoing PCI with DES and is often secondary to physician decision rather than
noncompliance. Premature discontinuation is associated with both insurance status
and clinical factors.
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Background: Glycoprotein IIb/IIIa inhibitors are recommended by guidelines in
patients with ST-segment elevation myocardial infarction (STEMI) treated with
primary percutaneous coronary intervention (PPCI). There are few studies directlyB48 JACC Vol 62/18/Suppl B j October 27–Novemcomparing these two agents. The aim of this study was to compare the effectiveness of
eptiﬁbatide relative to abciximab in patients with STEMI treated with PPCI.
Methods: This was an observational cohort study of 2083 patients who received
a GPIIb/IIIa inhibitor whilst undergoing primary percutaneous coronary intervention
(PPCI) from 2006 to 2012. Patients who did not receive a GPIIb/IIIa inhibitor were
excluded. The primary end-point was the ﬁrst major adverse cardiac event (MACE)
deﬁned as death, non-fatal myocardial infarction, stroke or target vessel
revascularisation.
Results: 1522 patients received abciximab and 561 received eptiﬁbatide. Differences
in baseline characteristics are outlined in Table 1. Patients receiving eptiﬁbatide had
higher rates of previous PCI and hypercholesterolaemia and were more likely to
undergo a procedure from the radial route. Unadjusted Kaplan-Meier analysis revealed
no signiﬁcant difference in 1-year event rates between patients given eptiﬁbatide
versus abciximab. Age-adjusted Cox analysis demonstrated no difference in 1 year
outcome between abciximab and eptiﬁbatide (HR 1.01 [95% CI 0.73-1.39]), which
persisted after multivariate adjustment (HR 1.37 [95% CI 0.93-1.96]). Regression
adjustment incorporating a propensity score (age, gender, ethnicity, previous MI, PCI
or CABG, diabetes, hypertension, hypercholesterolaemia, smoking status, presence or
absence of shock, and ejection fraction) into the hazards model as a covariate, showed
no difference in outcome (HR 1.21 [95% CI 0.83-1.54]).Conclusions: This observational data suggests eptiﬁbatide is associated with similar
outcomes to abciximab in patients with STEMI undergoing PPCI.
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Background: Patients undergoing stent implantation with high platelet reactivity
(HPR) on clopidogrel have a greater incidence of adverse ischemic events. However,
low HPR may increase major bleeding, which can also inﬂuence mortality.
Methods: ADAPT-DES was an 8,583 pt prospective, multicenter study of pts
receiving DES; routine platelet function testing (VerifyNow) was performed following
clopidogrel loading. We sought to characterize the association between HPR and stent
thrombosis (ST) and major bleeding at 1 year by separating pts into quintiles of HPR.
Results: The median PRU of the 5 quintiles was 57, 130, 187, 244, and 317
respectively (most to least reactive); 42.7% of patients had HPR as deﬁned by
PRU>208. HPR was associated with 1-year ST (1.3% vs. 0.5%, p¼0.0001), but was
also protective from major bleeding (5.6% vs. 6.7%, p¼0.04); both types of events
were independent predictors of 1-year mortality. There was a graded association
between PRU quintiles and ST (Table), whereas for major bleeding, the highest risk
occurred in the lowest PRU quintile, a ﬁnding that was signiﬁcant in multivariableber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PManalyses (Hazard Ratio 1.52 [1.17,1.97], p¼0.002). There was no signiﬁcant associ-
ation between PRU quintiles and mortality.Table. Event Rates Among Quintiles of PRU
1-year event
rates
Quintile
1
Quintile
2
Quintile
3
Quintile
4
Quintile
5
p(<95)
(95-
159)
(160-
215)
(216-
275) (>275)
Def/prob ST 0.49% 0.43% 0.79% 1.13% 1.33% 0.01
Major Bleeding 8.17% 5.81% 5.74% 5.27% 5.67% <0.01
Mortality 1.52% 1.55% 1.72% 2.37% 2.39% 0.15
Baseline
Characteristics CCB (n=2437) No CCB (n=6146) p-value
Mean age, years 65.510.7 62.910.8 <0.0001
Diabetes 39.8% 29.5% <0.0001
Hypertension 92.3% 74.6% <0.0001
Hyperlipidemia 79.6% 72.2% <0.0001
Acute Coronary
Syndrome
49.0% 52.7% 0.002
VerifyNow P2y12
Mean PRU 199.498.0 183.495.9 <0.0001
PRU > 208 47.9% 40.7% <0.0001
%inhibition 37.2% 41.1% <0.0001
1-Year Follow-up
(out of hospital)
CCB (n[1771) No CCB
(n[6811)
Death 3.2% 1.6% <0.0001
MI 2.5% 1.6% 0.01
MACE 3.4% 2.4% 0.01
Stent thrombosis
(deﬁnite/probable)
0.99% 0.66% 0.16
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a graded fashion, bleeding risk was conﬁned to pts in the lowest PRU quintile
(PRU<95). There was no demonstrable threshold effect for HPR and mortality,
perhaps due to the offsetting impact of bleeding and ischemic outcomes.
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Background: High platelet reactivity (HPR) is associated with poor prognosis in coro-
nary artery disease. Recently PLATO subgroup analysis showed that ticagrelor is better
clinical outcome than the clopidogrel,whichwas relatedwith lowHPR.Alsomany studies
reported that adjunctive cilostazol to dual antiplatelet therapy (DAPT) (so called triple
antiplatelet therapy; TAT) is better clinical outcome than DAPT, which was associated
with a greater antiplatelet effect at 30 days. Thus, this study was designed to compare the
effect of ticagrelor and TAT on platelet reactivity with PRU and ARU values.
Methods: This study was composed of total 65 patients underwent the coronary stenting.
All patients received a 600-mg loading dose of clopidogrel or a 180-mg loading dose of
ticagrelor and concomitant aspirin therapy. After patients underwent coronary stenting,
theywere nonrandomly assigned to 1 of 4 groups:DAPT group (n¼15), clopidogrel of 75
mg daily; ticagrelor group (n¼20), ticagrelor of 180 mg daily; TAT group (n¼15),
adjunctive cilostazol of 100mg twice daily to clopidogrel of 75mg daily; and triple switch
group (n¼15), switch of ticagrelor to TAT since 3rd day. The platelet reactivity was
assessed by ARU and PRU values at day 2 and day 7, respectively.
Results: The average PRU value was lower in ticagrelor and TAT group than DAPT
throughout the study period but the average ARU value did not differ among the 4
groups. The 2nd day average ARU was lower in the TAT group than ticagrelor group
(405 vs. 510, p<0.01) and there was no signiﬁcant difference on 7th day average ARU
value. In ticagrelor group, 7th day average ARU is lower than 2th day ARU (458 vs.
510, p<0.05). Compared with TAT group, ticagrelor group had signiﬁcantly lower PRU
level at 2nd day and 7th day, respectively (91 vs. 162, p<0.05, 50 vs. 163, p<0.01). The
2nd day average PRU value of triple switch group was 70 which was similar to PRU of
ticagrelor group and 7th day average PRU (151) was similar to that of TAT group.
Conclusions: The ticagrelor and TAT therapy had the lower PRU level than DAPT
and especially, ticagrelor showed the lowest incidence of HPR. This indicates that
ticagrelor is more effective in HPR treatment than TAT.
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Background: In patients undergoing PCI for STEMI/NSTEMI, a loading dose (LD)
of the new potent P2Y12 inhibitors, thanks to their early onset of platelet inhibition,
can be administered immediately after the diagnostic coronary angiography. However,
there are no data about the level of platelet inhibition they provide during and
immediately after the PCI with this timing of administration. We sought to assess and
compare the action of prasugrel, ticagrelor and clopidogrel during and immediately
after the PCI for STEMI/NSTEMI when administered with this speciﬁc timing.
Methods: Seventy-two patients with STEMI/NSTEMI undergoing urgent PCI with
heparin monotherapy were randomized after the coronary angiogram to receive 60 mg
prasugrel LD (n 24) or ticagrelor 180 mg (n 24) or clopidogrel 600 mg (n 24).
Residual platelet reactivity was assessed with VerifyNow at baseline, 30 min and 120
min after the LD. A 24 h platelet reactivity assessment with Light Transmission
Aggregometry (LTA) was also performed.
Results: Platelet reactivity units (PRU) 30 min after the LDwere 305 (70), 286 (59)
and 280 (70) in the prasugrel, ticagrelor and clopidogrel group, respectively (p¼NS).
PRU 120 min after the LD were 220 (100), 210 (88) and 163 (101), respectivelyJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstr(overall p 0.1). At 120 min PRU post hoc analysis only clopidogrel Vs ticagrelor were
signiﬁcantly different (p¼ 0.03). Furthermore, high residual platelet reactivity (HRPR)
(PRU> 240) was found in 52%, 28% and 58% of patient in the prasugrel, ticagrelor and
clopidogrel group, respectively (p¼ 0.12). No case of HRPR (deﬁned as LTA assessed
residual platelet activity> 65%) were found in the prasugrel and ticagrelor group while
55% of patients showed HRPR in the clopidogrel group (p< 0.01). At multivariate
analysis no independent predictors of HRPR at 120 min were found.
Conclusions: None of the drugs studied achieved an effective platelet inhibition
during the PCI when administered immediately after the coronary angiogram in
patients with STEMI/NSTEMI. At 120 min only ticagrelor achieved a signiﬁcantly
higher inhibition of platelet reactivity when compared to clopidogrel. A high
percentage of HRPR both at 30 min and 120 min was present in all groups.
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Background: Many patients with coronary artery disease receive concomitant treat-
ment with clopidogrel and calcium channel blockers (CCB). Prior small studies have
raised concerns regarding the effect of CCB on clopidogrel-related platelet reactivity
and its clinical signiﬁcance. We examined this relationship in the large scale
Assessment of Dual Anti-Platelet Therapy with Drug-Eluting Stents (ADAPT-DES)
registry.
Methods: A total of 8,583 patients had P2Y12 platelet reactivity testing using the
VerifyNow point-of-care assay after successful, non-complicated PCI with DES
implantation. All patients were treated with aspirin and clopidogrel, and were followed
for 1 year. CCB were prescribed at the discretion of treating physicians.
Results: At the time of the post-procedure P2Y12 test, 2437 (28.4%) pts were on
CCB, and 6146 (71.6%) were not. Major baseline characteristics, P2Y12 results and
1-year follow-up events are summarized in the Table. The use of CCB was an
independent predictor of higher platelet reactivity units (PRU) in a linear regression
model (p<0.0001), and was independently associated with high platelet reactivity as
deﬁned as PRU >208 (OR 1.16, p¼0.014). At discharge, 1771 (20.6%) pts were
prescribed CCB, and 6811 (79.4%) were not. In propensity-stratiﬁed proportional
hazards regression models, the use of CCB was not independently associated with
adverse outcomes.acts/POSTER/Antiplatelets and Antithrombins B49
